U.S. FDA Accepts sBLA for ENFLONSIA to Update its Respiratory Syncytial Virus Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Merck's LIPFENDRA® is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
KEYTRUDA® as Monotherapy Significantly Improved Progression-Free Survival in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient Tumors Compared to Chemotherapy
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each With Padcev® , as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , each with Trodelvy® as First-Line Treatment of PD-L1+ Advanced Triple-Negative Breast Cancer
European Commission Approves KEYTRUDA® Plus Padcev® as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis
